Johnson & Johnson at ASH 2026
Dec 12–15, 2026 New Orleans, LA ~30k attendees Website
Johnson & Johnson exhibits at Booth 2913 at ASH 2026 in New Orleans. Its presence centres on multiple myeloma, supporting symposia on bispecific antibodies in community practice, updated guidelines and what to use after relapse. It also supports symposia on earlier diagnosis of AL amyloidosis and on menin inhibitors in acute myeloid leukemia.
| Organization | ASH 2026 Attendance |
|---|---|
Johnson & Johnson New Brunswick, NJ | |
Global healthcare company that develops, makes and sells prescription medicines and medical technologies, including myeloma and other blood cancer therapies. | Booth Exhibiting at Booth 2913 Sat, Dec 1211:00am–5:00pmSun, Dec 1310:00am–5:00pmMon, Dec 1410:00am–2:00pm Symposium Fri Dec 11 11:00am–2:00pm Actionable Approaches to AL Amyloidosis Care: Diagnosing Earlier, Treating Smarter, Managing Together Diagnosing light-chain amyloidosis earlier, personalizing treatment including fibril-targeting drugs, supporting patients, and improving team workflows. Symposium Fri Dec 11 7:00am–10:00am Breaking News: Launching Bispecific Antibodies for Multiple Myeloma in Community Practice Bringing bispecific antibodies for multiple myeloma into community clinics, with patient selection, sequencing, toxicity management, and outpatient setup. Symposium Fri Dec 11 3:00pm–6:00pm Live Hot Seat™: Advancing Precision Care in Acute Myeloid Leukemia With the Integration of Menin Inhibitors Menin inhibitors for genetically defined acute myeloid leukemia, covering patient selection, combinations, resistance, and differentiation syndrome. Symposium Fri Dec 11 3:00pm–6:00pm Myeloma Challenge! Test Your Knowledge of Updated Guidelines and Evidence-Based Practice Guideline-based myeloma care from smoldering disease to late relapse, including three- or four-drug regimens, residual disease testing, and newer immunotherapies. Symposium Fri Dec 11 7:00am–10:00am Next in Line for Relapsed/Refractory Myeloma: Sequencing Strategies With T-Cell Engagers, Next-Generation CAR-T, and Innovative MOAs Sequencing relapsed myeloma treatments as next-generation CAR-T, multi-target T-cell engagers, and new drug classes arrive, plus managing their toxicity. |
Instantly find 20 buyers from Johnson & Johnson
Get a list of who you should contact, their contact info, and what to say.
Totally free and instant, no sign up necessary!
Not affiliated with or endorsed by the American Society of Hematology (ASH). Submit a correction